AviadoBio and Astellas Pharma announced an exclusive option and license agreement for AVB-101, an investigational, AAV-based gene ...
The asset, AVB-101, is being evaluated in a phase 1/2 trial in frontotemporal dementia with progranulin mutations. The deal ...
The Japanese big pharma adds the new gene therapy candidate to its pipeline in a US$50 million deal in equity and upfront ...
Astellas has turned to AviadoBio to further boost its gene therapy pipeline, paying the British biotech $50 million in equity ...
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license ...
Astellas has added another gene therapy to its pipeline, taking an option on a clinical-stage candidate for a rare genetic ...
Aviadobio Ltd. has entered a potential $2.18 billion license and commercialization agreement for its frontotemporal dementia gene therapy, AVB-101, with Astellas Pharma Inc. Astellas is making a $20 ...
The agreement leverages King's College London spin-out company's expertise in developing targeted gene therapy for ...
Velocity, A Managed Solutions Company, a technology solution and service provider of voice and data networking and connectivity for multi-location enterprises across multiple industries, announces its ...
Astellas will make a $20 million equity investment in AviadoBio for the option to exclusively develop and commercialize AVB-1010.
https://recalls-rappels.canada.ca/en/alert-recall/various-brands-beef-jelly-tongue-products-recalled-due-listeria-monocytogenes#tablefield-node-76298-field_affected_products-0 Toll-free: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback